Analyst Research

Report Title Price
Provider: ValuEngine, Inc.
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: GlobalData
$125.00
Provider: Wright Reports
$75.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Genmab launches private placement


Thursday, 23 Jan 2014 11:33am EST 

Genmab A/S:Launches private placement of a limited number of new shares to selected institutional investors.Says the new shares will be issued at market price to be determined through an accelerated book-build process, which will begin immediately.Says the private placement is expected to constitute new shares equivalent to about 7 pct of Genmab's current registered share capital and will in all circumstances be limited to a maximum of 5,175,572 new shares with a nominal value of 1 Danish crown each.Says the maximum number of shares is equivalent to about 9.99 pct of Genmab's current registered share capital which is the limit for requiring the publication of a prospectus.Says potential uses for the net proceeds from the transaction may include, among other things, clinical development of HuMax-TF-ADC and progressing Genmab’s pipeline of pre-clinical projects towards clinical development. 

Company Quote

248.5
-3.9 -1.55%
24 Oct 2014